Discontinued — last reported Q3 '23
ResMed Accrued Contingent Liabilities remained flat by 0.0% to $800.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.3%, from $700.00K to $800.00K. Over 3 years (FY 2022 to FY 2025), Accrued Contingent Liabilities shows a downward trend with a -69.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase may signal rising legal, regulatory, or operational risks that could impact future cash flows.
This represents estimated liabilities for events that are probable and reasonably estimable, such as legal settlements,...
Varies significantly by industry and litigation environment; peers in the same sector often face similar risk profiles.
accrued_contingent_liabilities| Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $24.20M | $22.40M | $24.10M | $29.70M | $32.60M | $28.90M | $29.20M | $35.00M | $800.00K | $800.00K | $700.00K | $700.00K | $700.00K | $700.00K | $800.00K | $800.00K |
| QoQ Change | — | -7.4% | +7.6% | +23.2% | +9.8% | -11.3% | +1.0% | +19.9% | -97.7% | +0.0% | -12.5% | +0.0% | +0.0% | +0.0% | +14.3% | +0.0% |
| YoY Change | — | — | — | — | +34.7% | +29.0% | +21.2% | +17.8% | -97.5% | -97.2% | -97.6% | -98.0% | -12.5% | -12.5% | +14.3% | +14.3% |